Impact of Pharmaceutical Innovation in HIV/AIDS Treatment during the Highly Active Antiretroviral Therapy (HAART) Era in the US, :
|
|
- Pierce Webster
- 6 years ago
- Views:
Transcription
1 White Paper Impact of Pharmaceutical Innovation in HIV/AIDS Treatment during the Highly Active Antiretroviral Therapy (HAART) Era in the US, : An Epidemiologic and Cost-impact Modeling Case Study Michael J. Lacey, MsC 1, George J. Hanna, MD 2, Jeffrey D. Miller, MS 3, Talia S. Foster, MS 3, Mason W. Russell, MAPE 3 1MJL3 Group LLC, Newton, MA, USA; 2Princeton, NJ, USA; 3Truven Health Analytics, Cambridge, MA, USA December 2014
2 Tremendous strides have been made over the past 25 years in the prevention and treatment of HIV Infection and AIDS (HIV/AIDS). Since peaking in 1995, death rates have fallen nearly 85%.
3 Introduction Tremendous strides have been made over the past three decades in the prevention and treatment of HIV infection and AIDS (HIV/AIDS). The HIV/AIDS pandemic was first recognized in 1981 and it was initially associated with considerable morbidity (opportunistic infections and cancers) and high mortality in a previously young and healthy population [1]. In 1990 HIV/AIDS was ranked 7th among diseases and injuries most likely to cause premature mortality in the U.S. By 2010, HIV/AIDS ranked 23rd on this list [2]. Today with access to treatment, what was once an acutely fatal illness is now largely a manageable chronic condition. Drug development efforts resulted in the first FDA- approved medicine in 1987, the nucleoside reverse transcriptase inhibitor (NRTI) zidovudine, a subset of the broader class of antiretrovirals (Figure 1). However, its use as monotherapy produced modest, short- lived effects. Starting in 1991, additional nucleosides were approved by FDA for HIV infection, allowing the possible use of combination antiretrovirals to treat HIV disease. The first non- nucleoside class antiretroviral, the protease inhibitor saquinavir, was approved by FDA in December 1995, and was followed by approval of additional protease inhibitors as well as non- nucleoside reverse transcriptase inhibitors (NNRTIs) and other classes such as integrase inhibitors. This ushered the era of highly active antiretroviral therapy (HAART), defined as a regimen consisting of multiple antiretroviral drugs in combination. HAART, now often composed of two NRTIs in combination with a third antiretroviral of a different class (commonly a protease inhibitor, a NNRTI or an integrase inhibitor), proved capable of profound and durable suppression of HIV in an infected individual. Based on compelling data from clinical trials of combination antiretroviral therapy, HIV treatment guidelines in 1996 started recommending combination antiretroviral regimens, which later came to be know as HAART. In parallel, sharp declines in morbidity and mortality among persons living with HIV/AIDS were noted starting between and decreases became dramatic starting in 1996 [1]. In the US, age- adjusted death rates due to HIV disease have declined from 16.2 per 100,000 persons in 1995 to 2.6 per 100,000 in In other words, since the introduction of these revolutionary treatments, the death rate has fallen nearly 85% [3]. Many factors have contributed to the declines in HIV/AIDS death rates. These include public health prevention programs, greater access to medical care for at risk populations, improvements in opportunistic infection prophylaxis and treatment, and greater clinical experience of providers in managing HIV/AIDS. However, the ability to suppress HIV in infected individuals with antiretroviral combinations, even with early HAART regimens, directly resulted in marked immunologic improvements and decreases in morbidity and mortality [4-6].
4 Figure'1.''Timeline'of'early'an2retroviral'drug'discovery'! 1981! Ini)al!reports!of!an!acquired!immune!deficiency!syndrome,!later!known!as!AIDS.! 1984! Na)onal!surveillance!of!AIDS!cases!fully!underway.! 1985! FDA!licensure!of!HIV!an)body!test!to!diagnose!HIV!infec)on.! 1987! FDA!approves!1st!an)retroviral,!the!nucleoside!zidovudine.! 1991! 1995! 1996! FDA!approves!2nd!an)retroviral,!the!nucleoside!didanosine,!allowing!possibility!of! combina)on!an)retroviral!therapy.! FDA!approves!1st!nonNnucleoside!class!an)retroviral,!the!protease!inhibitor!saquinavir,! ushering!era!of!highly!ac)ve!an)retroviral!therapy!(haart).! First!interna)onal!an)retroviral!treatment!guidelines!panel!(Interna)onal!AIDS!Society!USA)!to! recommend!combina)on!an)retroviral!therapy.! In other words, since the introduction of these revolutionary treatments, the death rate has fallen nearly 85% [3]. The progress that has been made against HIV/AIDS over the past several decades has been incredible. This paper has undertaken to presuppose the existence of an alternative reality: where would we be today had HAART and all the innovations which followed never come into existence? Had innovation stopped prior to the introduction of these medicines, how many more may have died prematurely? What sort of social and economic losses would have been realized as a result of the additional lives that were lost? In pursuit of these questions this paper has constructed a conceptual framework for analyzing the value brought to patients and society as a result of the deaths that were avoided and the years of life gained in the decades following the introduction of HAART. This exercise focuses specifically on the value gained as a result of reductions in mortality. Construction of Analytical Framework The enormous social cost of HIV/AIDS is reflected in years of potential life lost (YPLL) due to premature mortality when compared to the risk- adjusted life expectancy in the absence of HIV/AIDS. The U.S. Centers for Disease Control (CDC) estimates that from 1995 to 2010 the YPLL among persons who lived with HIV/AIDS declined from a high number of 593,300 lost life- years due to premature mortality in 1995 to a low of 76,600 lost life- years due to premature mortality in These improvements closely mirror the observed reduction in mortality rates (Figure 2). Life- expectancy post- HIV infection has improved dramatically since the early 1990 s and in the United States and Canada life expectancy among treated HIV- positive individuals now approaches that of the general population [7, 8].
5 Figure'2.''Age+adjusted'years'of'poten6al'life'lost'(YPLL)'before'age'75' among'persons'who'lived'with'hiv/aids'per'100,000'popula6on'in'the' US,' '' 700.0# 600.0# 1994J1996# Start'of'clinical'usage'of'combina6on'an6retroviral'therapy'and'HAART' YPLL#Per#100,000# 500.0# 400.0# 300.0# 200.0# 100.0# 0.0# 1990# 1991# 1992# 1993# 1994# 1995# 1996# 1997# 1998# 1999# 2000# 2001# 2002# 2003# 2004# 2005# 2006# 2007# 2008# 2009# 2010# Year# Source:#Table#21.#Years#of#potenAal#life#lost#before#age#75#for#selected#causes#of#death,#by#sex,#race,#and#Hispanic#origin:#United#States,#selected#years#1980J2010.# Health,#United#States,#2013# There is also a significant social and economic burden of treating HIV/AIDS. From an economic perspective the value of prevention is often quantified as the direct medical care costs for HIV infection averted. Recent research has estimated the direct lifetime cost of treating a new HIV infection ranged from $253,000 to $402,000 from time of infection [9]. Cost of treating HIV/AIDS has been estimated to be $19,955 per patient per year (2006 dollars). This includes $10,205 in HAART drug costs, $2,670 in hospitalization costs and $7,080 in other costs [10]. The value of averting HIV infections through prevention strategies has been estimated using a variety of approaches. Using a simulation based model using population level incidence and transmission rates, direct cost savings over the period due to prevention efforts was estimated to be $129.9 billion in costs savings (1996 dollars) in the base case and ranged from $70.3 billion to $515.3 billion depending on Economic Costs Direct and Indirect Direct costs include those associated with pharmaceuticals, hospitalizations, physician and specialist visits and other medical- care that consumes tangible healthcare resources. Indirect costs are those related to lost economic productivity due to illness or premature mortality. For example lost wages due to work loss for the patient and their caregivers. These costs are called indirect costs since because they are not directly involved in healthcare delivery but are nonetheless still contribute to the total value of health services and interventions. assumed transmission rate [11]. A second study using a different methodology aggregated the direct and indirect cost of an HIV/AIDS diagnosis in the US. Cumulatively the direct costs of new HIV infections were estimated to be $36.4 billion in 2002, including $6.7 billion in direct costs and $29.7 billion in
6 indirect costs [12]. Reductions in resource utilization related to hospitalization also closely follow improvements in morbidity and mortality (Figure 3). This has occurred despite the fact that the overall prevalence of persons living with HIV has increased from 760 thousand in 1996 to 1.2 million as of 2012 [3]. 80.0# Figure%3.%%Hospitaliza8on%Rates%per%100,000%for%HIV=Related%Infec8ons%in% the%us,%1993=2012%% 1994:1996# Start%of%clinical%usage%of%combina8on%an8retroviral%therapy%and%HAART% 70.0# 60.0# Rate%Per%100,000% 50.0# 40.0# 30.0# 20.0# 10.0# 0.0# 1993# 1994# 1995# 1996# 1997# 1998# 1999# 2000# 2001# 2002# 2003# 2004# 2005# 2006# 2007# 2008# 2009# 2010# 2011# 2012# Year% Source:#Table#2.#Years#1993:2001.#Lichtenberg,#FR.##The#Impact#of#Increased#UJlizaJon#of#HIV#Drugs#on#Longevity#and#Medical#Expenditures:#An#Assessment#Based#on# Aggregate#U.S.#Time:Series#Data.##NBER#Working#Paper#No.#12406#July#2006#JEL#NO.#I12,#J1,#033.###Years#2002#:2012#EsJmated#from#NaJonal#InpaJent#Sample.### SPECTRUM#data,#2014.# Study Objectives Assessing the value of prevention of early mortality requires estimating the added benefit of the expected economic productivity among individuals with increased lifespan minus the added costs of caring for individuals over time. The purpose of this analysis is to estimate the net- economic benefit of prevention and treatment during the early HAART era spanning 1996 through We use data from a variety of sources and statistical modeling techniques to derive our estimates. A simplified schematic representation of the model is shown below (Figure 4).
7 Figure'4.'Cost'Impact'of'HIV/AIDS'Treatment'During'the'HAART'Era,'1996C2010' Net$Economic$Benefit$(NEB)$=$$Added$Economic$Benefit$ $ $ $$ $Added$Treatment$Costs$ Costs)of)Treatment) Non/HAART)) costs)of) Added)Life/ Years) HAART)Costs) of)added) Life/Years) Net'Economic'Benefit' Mortality) Averted) Life/Years) Gained) Increased) Wages) Economic)Benefit)of)Treatment) The focus of our research is to estimate the value of innovation in the prevention and treatment of HIV/AIDS by developing a statistical model to simulate a world without antiretroviral and HAART innovation (including the many innovations that followed). We have structured our case study around three questions: 1. In the US setting, what are the differences in estimated mortality rates (per 100,000) between actual observed HIV/AIDS population and a hypothetical HIV/AIDS cohort without access to antiretroviral and HAART therapies over the period ? 2. What are the differences in number of premature deaths and years of potential life lost (YPLL) between these two cohorts? 3. What was the net economic value and cost effectiveness from averting premature mortality minus cost of treating HIV/AIDS among survivors between these cohorts?
8 Methods To estimate the value to patients and society of therapy during the HAART era we developed an epidemiologic and cost- impact model in MS Excel. We first compare actual death rates among persons with HIV disease observed during the study observation period ( ) to a cohort in a hypothetical scenario in which antiretroviral agents and HAART regimens were not developed. We used actual death rates from the period ( ) defined as the pre- HAART period to develop a statistical model to project expected death rates during the HAART period ( ). Death rates were taken from published CDC data [3]. Projected death rates were estimated using linear regression with exponential smoothing. Net deaths averted were defined as the net difference in expected versus observed cases in each year of the study period. Life years lost per case due to premature mortality was estimated based on CDC estimates of years of potential life lost (YPLL) from premature mortality [3]. Total YPLL equals YPLL per case multiplied by total number of deaths averted. Use of Cost-Impact Models in the Evaluation of Health Interventions and Therapies Cost- impact models help estimate the total financial impact of a public health program or therapy within a population. In this case study we take the perspective of the entire US society. Cost impact is measured by the net difference between the economic value (in US dollars) of benefits realized by a new program or therapy minus the costs of providing the new service or therapy. Net Economic Benefit (NEB) = Added Economic Benefit - Added Treatment Costs For example, one of the primary impacts of HAART therapy is the marked reduction in mortality rates among persons living with HIV infection. Our cost impact model accounts for both the dollar value of wages earned by persons who are now alive due to the therapy and compare this to the therapy costs and medical resources (i.e., hospitalizations, specialist visits, drug therapy) used by these individuals. The cost impact (Net Economic Benefit) is the difference between these benefits and costs. Net Economic Benefit (NEB) was chosen as a suitable measure as it takes into account the economic benefit associated with increased life expectancy balanced against the added cost of treatment for the increased life expectancy due to improved outcomes. Patients who live longer will participate in the labor force and contribute to increased societal productivity. Counterbalancing this effect is the marginal cost of caring for persons living with HIV over the extended life expectancy. We estimated productivity benefit based on US National Median Wage in 2012 [13] and inflated by 30% [13] to account for the value of employee benefits. This value was further adjusted to account for individuals not participating in the labor force due to a variety of reasons including unemployment, inability to participate in the labor force or retirement [14]. These income estimates were then adjusted to 2010 levels using the National Wage Inflation Index (2012) [15].
9 Annual costs of HIV treatment per year are based on a recent study of a large sample of persons living with HIV disease from more than 10 participating treatment centers. Average annual costs were estimated to be $19,599 including approximately $10,203 for HAART per year (2006 dollars) [10]. Costs were then inflated to 2010 dollars [15]. Following standard methodology, all cost measures were then discounted by 3% per year to arrive at a net present value for the costs of care in each year. The aggregate cost of treating HIV (including costs of HAART and non- HAART costs such as hospitalizations, specialist visits, and drugs other than HAART) was estimated as the discounted cost per year multiplied by the number of life years saved [16]. The cost impact model compares the dollar value of wages earned by persons who are now alive due to the therapy to the costs of therapy and medical resources (i.e., hospitalizations, specialist visits, drug therapy) used by these individuals. Therefore, the cost impact (Net Economic Benefit) is the difference between these productivity gains and added direct medical costs.
10 Results The model illustrates the difference between actual mortality rates and a scenario of what might have happened if innovation had essentially stopped just prior to the advent of HAART therapies beginning during the period The model found a substantial number of premature deaths averted during the HAART era. The projected mortality curve reflects a continuation of the continuous increase in annual mortality rates observed prior to the HAART era. The model predicts a slowing of the rate of increase to reflect the likely changes public health prevention efforts if HAART therapies were never developed. We adopted this assumption to ensure that we did not overestimate the predicted mortality ratio. Our primary result is that an estimated 862,396 premature deaths were averted since the beginning of the HAART era. This result is depicted in Figure 5. The white area depicts actual mortality rates (%). The shaded blue area represents the difference between the projected and actual mortality rates over the entire period. Each premature death represents more than one year of potential life lost based on the methodology described above. For example if a person dies at age 30 and their life expectancy was 70 years then this individual would represent = 40 years of potential life lost (YPLL). Conversely, if this person were kept alive due to improved treatment the number of years of potential life gained (YPLG) would be 40 YPLG. Model results show that a cumulative 27,685,660 life years were gained from deaths averted over the period from in the US (Figure 5). The cumulative value of increased wages earned was $857 billion. Total HIV/AIDS treatment costs (HAART- related and non- HAART related) were $242 billion. Added HAART related costs were $126 billion (52%) and non- HAART related costs were $116 billion (48%) of the total $242 billion in added costs. Net Economic Benefit (NEB) over the period was $615 billion ($857 billion minus $242 billion)(figure 6).
11 & 10.00%$ Figure&5.&&Age4adjusted&death&rates&rates&for&HIV&disease&in&the&US& ,&Actual&versus&Projected& 9.00%$ 8.00%$ 7.00%$ Start&of&clinical&usage&of&combinaKon& ankretroviral&therapy&and&haart& 1994X1996$ Projected$Mortality$ Annual&Mortaliy&Rate& 6.00%$ 5.00%$ 4.00%$ 3.00%$ Deaths$Averted$$ (862,396)$ Years$of$PotenFal$Life$Gained$(YPLL)$ (27.7$million)$ 2.00%$ Actual$Mortality$ 1.00%$ 0.00%$ 1987$ 1988$ 1989$ 1990$ 1991$ 1992$ 1993$ 1994$ 1995$ 1996$ 1997$ 1998$ 1999$ 2000$ 2001$ 2002$ 2003$ 2004$ 2005$ 2006$ 2007$ 2008$ 2009$ 2010$ Source:$Actual$Mortality$Rates.$Table$31.$$Death$rates$for$human$immunodeficiency$virus$(HIV)$disease,$by$sex,$race,$Hispanic$origin,$and$age:$ Year& United$States,$selected$years$1987X2010.$$Health$United$States,$2013.$$Projected$Mortality$Rates$based$on$projecFon$model$ Figure'6.'Net'Economic'Benefit'of'HAART'Therapies,'1996?2010.' Factor' Benefit' Cost' Cumula&ve)Value)of)Produc&vity)Increase) $857)B*) Cumula&ve)Value)of)HAART)Costs)) $126)B) Cumula&ve)Value)of)NonEHAART)Costs) $116)B) Total)HIV/AIDS)Treatment)Costs) $242)B) Net'Economic'Benefit' $615'B' *B)=)billions)
12 Discussion In this investigation, we focused on the most objective measure of HAART effectiveness, the decrease in mortality (and increase in life expectancy). Several factors have contributed to the decline in HIV/AIDS- related mortality in the US, including public health prevention programs, improvements in opportunistic infection prophylaxis and treatment, greater clinical experience of providers in managing HIV/AIDS, as well as availability of antiretroviral therapy. Disentangling these factors to assess the contribution of only one of them is challenging. Nonetheless, clinical trial data clearly confirm the profound effect of combination antiretroviral regimens on morbidity and mortality, even with early HAART regimens that lacked the tolerability, durability of viral suppression, and ease of administration of modern regimens [4, 5]. Furthermore, the early- observed decline in HIV/AIDS mortality was strongest in patients prescribed HAART regimens compared to those on less optimal or no antiretroviral therapy [6]. The potentially synergistic two- way interaction between these factors should be borne in mind. For example, availability of effective treatments may increase desirability and acceptability of testing and counseling programs from a patient perspective, since a positive diagnosis no longer is a hopeless condition, and a patient at risk is less afraid of a potential positive test result. This may lead to increased testing and counseling with larger impact on preventing infection of HIV- negative individuals. From a public health perspective, availability of testing and counseling programs not only serves as a prevention program for those who are HIV- negative, but also enables connection of newly diagnosed HIV- positive individuals into earlier and more effective care, with downstream improvements in morbidity and mortality. Such synergistic interactions between factors are difficult to control in a model and may underestimate the effect of a single factor. Additionally, ongoing innovation in antiretroviral drug development has resulted in the availability of more convenient, better tolerated, durable and safer HAART regimens, some of which are now available as single- tablet regimens taken once daily. This, along with the recognition that immunological damage from HIV can occur early during the time course of the infection, has also influenced clinical practice and timing of initiation of treatment. US guidelines recommend starting treatment earlier in the disease course in order to optimize long term morbidity and mortality benefits [17]. The actual progressive decreases in mortality over time likely reflect in part these two additional factors. Therefore projected estimates of mortality and economic benefits may increase with time since the early HAART years. HAART has been successful not only in preventing AIDS and death in HIV- infected individuals, but also markedly reducing the transmission rate of HIV from infected individuals on therapy to their partners [18]. Treatment therefore may also serve as prevention of transmission, and our model does not directly assess this beneficial effect of HAART. Similarly, it is worthwhile to note in the absence of the availability of HAART regimens, a number of other interventions may have sought to ameliorate the impact of this public health crisis. For instance, in the absence of effective treatment options there may have been a scale up in public health and behavioral interventions as well as shifts in non- pharmaceutical based provision of healthcare services that may have influenced the trajectory of the disease. The many unknowns of a world in which effective HIV/AIDS therapy had not emerged represent the inherent challenges in projecting the epidemiology of disease. Nonetheless, the impact of HAART is widely recognized to have provided tremendous value to patients and society. This analytic framework is intended to demonstrate in objective terms the benefit of innovation and the important role that medicines play in transforming the treatment of disease.
13 Antiretroviral drug development has been an example of historical success of rapid and highly targeted drug development, with only 6 years between recognition of the disease and the first antiretroviral approval, and with over 25 unique antiretrovirals approved in subsequent years [19]. The striking improvements in morbidity and mortality of HIV/AIDS have been largely due to pharmaceutical innovation that produced effective antiretroviral therapy and HAART, with significant social net economic benefit. The results of this analysis suggest that as a result of HAART and the subsequent innovations that followed, an estimated 862 thousand premature deaths were avoided, 27 million life- years were saved, and $615 billion in economic value was gained in the United States alone. This example of antiretroviral drug development makes a strong case for continued investment and innovation in pharmaceutical research and development aiming to address serious unmet medical needs.
14 References 1. Centers for Disease Control and Prevention, Epidemiology of HIV/AIDS - United States, , in Morbidity and Mortality Weekly Report (MMWR). 2006, Centers for Disease Control and Prevention,: Atlanta, GA. 2. US Burden of Disease Collaborators, The state of US health, : burden of diseases, injuries, and risk factors. JAMA, (6): p National Center for Health Statistics.", Health, United States, 2013: With Special Feature on Prescription Drugs. Hyattsville, MD Cameron, D.W., et al., Randomised placebo- controlled trial of ritonavir in advanced HIV- 1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet, (9102): p Hammer, S.M., et al., A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med, (11): p Palella, F.J., Jr., et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med, (13): p Schackman, B.R., et al., The lifetime cost of current human immunodeficiency virus care in the United States. Med Care, (11): p Samji, H., et al., Closing the gap: increases in life expectancy among treated HIV- positive individuals in the United States and Canada. PLoS One, (12): p. e Farnham, P.G., et al., Updates of lifetime costs of care and quality- of- life estimates for HIV- infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr, (2): p Gebo, K.A., et al., Contemporary costs of HIV healthcare in the HAART era. AIDS, (17): p Farnham, P.G., et al., Medical costs averted by HIV prevention efforts in the United States, J Acquir Immune Defic Syndr, (5): p Hutchinson, A.B., The Economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr, (4). 13. US Social Security Administration, Average and Median Amounts of Net Compensation (accessed May 14, 2014). 14. Bureau of Labor Statistics (BLS), C.P.S.C., Labor Force Participation Rates by Sex and Race or Hispanic Ethnicity, US Bureau of Labor Statistics, Consumer Price Index for All Urban Consumers (CPI- U): U.S. city average, by expenditure category and commodity and service group Stover, J., T. Brown, and M. Marston, Updates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children. Sex Transm Infect, Suppl 2: p. i Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV- 1- infected adults and adolescents. Available at Accessed November 28, Cohen, M.S., et al., Prevention of HIV- 1 infection with early antiretroviral therapy. N Engl J Med, (6): p United States Food and Drug Administration, Antiretroviral drugs used in the treatment of HIV infection. Accessed November 26, 2014.
15 FOR MORE INFORMATION To engage in further discussions about this white paper or to speak with us about how we can assist you with your next research project, please send us an at ABOUT TRUVEN HEALTH ANALYTICS Truven Health Analytics delivers unbiased information, analytic tools, benchmarks, and services to the healthcare industry. Hospitals, government agencies, employers, health plans, clinicians, pharmaceutical, and medical device companies have relied on us for more than 30 years. We combine our deep clinical, financial, and healthcare management expertise with innovative technology platforms and information assets to make healthcare better by collaborating with our customers to uncover and realize opportunities for improving quality, efficiency, and outcomes. With more than 2,000 employees globally, we have major offices in Ann Arbor, Mich.; Chicago; and Denver. Advantage Suite, Micromedex, ActionOI, MarketScan, and 100 Top Hospitals are registered trademarks or trademarks of Truven Health Analytics. truvenhealth.com Truven Health Analytics Inc. All rights reserved. All other product names used herein are trademarks of their respective owners. This research was supported by funding provided by Pharmaceutical Research and Manufacturers of America (PhRMA).
Supplementary Material. In this supplement we derive the full form of the monetary and health costs of testing
Supporting document Supplementary Material In this supplement we derive the full form of the monetary and health costs of testing every years, and ; we derive the approximation shown in (1); and we justify
More informationEnhancing the Reliability of Physician Performance on Hospital Outcome Measures
White Paper Enhancing the Reliability of Physician Performance on Hospital Outcome Measures Robert Sutter, RN, MBA, MHA Brian Waterman, MPH October 2013 Table of Contents Introduction 1 Reliability of
More informationUp to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).
HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and
More informationImplementation of testing (and other interventions along the Continuum of Care)
Implementation of testing (and other interventions along the Continuum of Care) Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention U.S. Centers for Disease Control
More informationViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV
ViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV ViiV Healthcare is a company 100% committed to HIV, and we are always looking to move beyond the status
More informationSetting The study setting was the community. The economic analysis was conducted in the USA.
Estimated effectiveness and cost-effectiveness of federally funded prevention efforts on gonorrhoea rates in the United States, 1971-2003, under various assumptions about the impact of prevention funding
More informationPandemic Preparedness: Pigs, Poultry, and People versus Plans, Products, and Practice
SUPPLEMENT ARTICLE Pandemic Preparedness: Pigs, Poultry, and People versus Plans, Products, and Practice Julie L. Gerberding Centers for Disease Control and Prevention, Atlanta, Georgia Influenza pandemic
More informationEconomic analysis of initial HIV treatment: efavirenz- versus indinavir-containing triple therapy Caro J J, O'Brien J A, Miglaccio-Walle K, Raggio G
Economic analysis of initial HIV treatment: efavirenz- versus indinavir-containing triple therapy Caro J J, O'Brien J A, Miglaccio-Walle K, Raggio G Record Status This is a critical abstract of an economic
More informationINTERNAL QUESTIONS AND ANSWERS DRAFT
WHO CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION Background: INTERNAL QUESTIONS AND ANSWERS DRAFT At the end of 2012, 9.7 million people were receiving
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationThe cost-effectiveness of screening men who have sex with men for rectal chlamydial and
The cost-effectiveness of screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent human immunodeficiency virus (HIV) infection: Supplemental appendix 1. The model
More informationUNAIDS 2016 THE AIDS EPIDEMIC CAN BE ENDED BY 2030 WITH YOUR HELP
UNAIDS 2016 THE AIDS EPIDEMIC CAN BE ENDED BY 2030 WITH YOUR HELP WHY UNAIDS NEEDS YOUR SUPPORT Over the past 35 years, HIV has changed the course of history. The massive global impact of AIDS in terms
More informationAdvaMedDx Value Assessment Framework in Practice
AdvaMedDx Value Assessment Framework in Practice Application of the Comprehensive Assessment of the Value of Diagnostic Technologies Framework to Abbott s 4th Generation ARCHITECT HIV Antigen/Antibody
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationCLINICIAN INTERVIEW PHARMACY MANAGEMENT OF HIV AND OPPORTUNISTIC INFECTIONS IN A HOSPITAL SETTING. Interview with Christopher Miller, PharmD, BCPS
PHARMACY MANAGEMENT OF HIV AND OPPORTUNISTIC INFECTIONS IN A HOSPITAL SETTING Interview with Christopher Miller, PharmD, BCPS Dr Miller is currently employed in a joint position as an assistant professor
More informationMedication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 update of the prevailing industry influences impacting pharmacy outcomes This page intentionally left blank Trends impacting workers compensation pharmacy
More informationPrevention of HIV in infants and young children
WHO/HIV/2002.08 Original: English Distr.: General Prevention of HIV in infants and young children A major public health problem HIV among children is a growing problem, particularly in the countries hardest
More informationState of Alabama HIV Surveillance 2013 Annual Report Finalized
State of Alabama HIV Surveillance 2013 Annual Report Finalized Prepared by: Division of STD Prevention and Control HIV Surveillance Branch Contact Person: Allison R. Smith, MPH Allison.Smith@adph.state.al.us
More informationState of Alabama HIV Surveillance 2014 Annual Report
State of Alabama HIV Surveillance 2014 Annual Report Prepared by: Division of STD Prevention and Control HIV Surveillance Branch Contact Person: Richard P. Rogers, MS, MPH richard.rogers@adph.state.al.us
More informationStudy population The study population comprised HIV-infected pregnant women seeking antenatal care.
Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries Sweat M D, O'Reilly K R, Schmid G P, Denison J, de Zoysa I Record Status This is a critical abstract
More informationAidspan Review of a Study on the Costs and Health Impact of Continued Global Fund Support for Antiretroviral Therapy
An independent watchdog of the Global Fund, and publisher of Global Fund Observer P.O. Box 66869-00800, Nairobi, Kenya Web: www.aidspan.org Email: info@aidspan.org Phone: +254-20-418-0149 Fax: +254-20-418-0156
More informationPreventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis Bayoumi A M, Redelmeier D A
Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis Bayoumi A M, Redelmeier D A Record Status This is a critical abstract of an economic
More informationPertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A
Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationInsurance Providers Reduce Diabetes Risk Through CDC Program
Insurance Providers Reduce Diabetes Risk Through CDC Program ISSUE BRIEF JULY 2018 KEY TAKEAWAYS 86 million Americans 1 in 3 adults have pre-diabetes. Studies show that losing 5 to 7 percent of body weight
More informationEstimates of New HIV Infections in the United States
Estimates of New HIV Infections in the United States CDC HIV/AIDS FACT S A UGUS T 28 Accurately tracking the HIV epidemic is essential to the nation s HIV prevention efforts. Yet monitoring trends in new
More informationThe HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA)
Written Testimony for the Record to the House Subcommittee on Labor, Health and Human Services, Education and Related Agencies regarding FY 2018 Appropriations for HIV/AIDS Programs Submitted by Dr. Wendy
More informationThe Economic Burden of Hypercholesterolaemia
The Economic Burden of Hypercholesterolaemia November 2018 TABLE OF CONTENTS Acronyms 3 Executive Summary 4 Introduction 5 Approach 5 Structure of the report 5 Economic burden of hypercholesterolaemia
More informationThe cost-effectiveness of expanded testing for primary HIV infection Coco A
The cost-effectiveness of expanded testing for primary HIV infection Coco A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract
More informationEstimates of New HIV Infections in the United States
Estimates of New HIV Infections in the United States CDC HIV/AIDS FactS A u g u s t 28 Accurately tracking the HIV epidemic is essential to the nation s HIV prevention efforts. Yet monitoring trends in
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationHome testing and counselling with linkage to care. Becky L Genberg, Joseph W Hogan and Paula Braitstein
Home testing and counselling with linkage to care Becky L Genberg, Joseph W Hogan and Paula Braitstein Globally, researchers and programme implementers strive towards the ambitious UNAIDS goal of 90-90-90
More informationKey Messages for World Malaria Day 2009
INFORMATION RBM/WG/2009/INF.12 10 APR 2009 Draft document General distribution English Only Key Messages for World Malaria Day 2009 Counting Malaria Out to Reaching the 2010 Targets On the occasion of
More information5 $3 billion per disease
$3 billion per disease Chapter at a glance Our aim is to set a market size large enough to attract serious commercial investment from several pharmaceutical companies that see technological opportunites,
More informationTHE EARLY TREATMENT FOR HIV ACT: MEDICAID COVERAGE FOR PEOPLE LIVING WITH HIV
THE EARLY TREATMENT FOR HIV ACT: MEDICAID COVERAGE FOR PEOPLE LIVING WITH HIV INTRODUCTION The Early Treatment for HIV Act (ETHA) would allow states to extend Medicaid coverage to uninsured, non-disabled
More informationThe Long-term Economic Costs of Asthma
Issue Paper #13 The Long-term Economic Costs of Asthma By Phaedra Corso, University of Georgia Angela Fertig, University of Georgia Partnership for America s Economic Success 1 The views expressed are
More informationFinancial Resources for HIV: PEPFAR s Contributions to the Global Scale-up of Treatment
Financial Resources for HIV: PEPFAR s Contributions to the Global Scale-up of Treatment Joint WHO & UNAIDS Consultation with Pharmaceuticals and Stakeholders November 05 2012 Lara Stabinski, MD, MPH Medical
More informationHigh Impact HIV Prevention Services and Best Practices
High Impact HIV Prevention Services and Best Practices David W. Purcell, JD, PhD Deputy Director for Behavioral and Social Science Division of HIV/AIDS Prevention Centers for Disease Control and Prevention
More informationEffective Technology and Its Economic Benefits: The Case of Colonoscopy
Effective Technology and Its Economic Benefits: The Case of Colonoscopy Ross C. DeVol, Chief Research Officer Milken Institute The 2015 Dialogue for Action: Expanding Access Through Innovation Renaissance
More informationGlobal and National trends of HIV/AIDS
Research and Review Insights Research Article ISSN: 2515-2637 Global and National trends of HIV/AIDS Hikmat Bahadur Raya* Lecturer, Department of Population Studies, Tribhuvan University, Terhathum M.
More informationCenters for Disease Control and Prevention (CDC) Coalition C/o American Public Health Association 800 I Street NW Washington, DC,
Centers for Disease Control and Prevention (CDC) Coalition C/o American Public Health Association 800 I Street NW Washington, DC, 20001 202-777-2514 Donald Hoppert, Director of Government Relations, American
More informationTB/HIV/STD Epidemiology and Surveillance Branch. First Annual Report, Dated 12/31/2009
TB/HIV/STD Epidemiology and Surveillance Branch First Annual Report, Dated 12/31/29 This Enhanced Perinatal Surveillance Report is the first annual report generated by the Texas Department of State Health
More informationPOSITION STATEMENT ON HEALTH CARE REFORM NADP PRINCIPLES FOR EXPANDING ACCESS TO DENTAL HEALTH BENEFITS
POSITION STATEMENT ON HEALTH CARE REFORM THE NATIONAL ASSOCIATION OF DENTAL PLANS (NADP) is the nation s largest association of companies providing dental benefits. NADP members cover 136 million Americans
More informationChildren and AIDS Fourth Stocktaking Report 2009
Children and AIDS Fourth Stocktaking Report 2009 The The Fourth Fourth Stocktaking Stocktaking Report, Report, produced produced by by UNICEF, UNICEF, in in partnership partnership with with UNAIDS, UNAIDS,
More informationHere are some of the steps (greatly simplified) and gaps that can occur in the HIV Treatment Cascade:
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Alberta Reducing deaths by strengthening the HIV Treatment Cascade 20 May 2014 In Canada and other high-income countries, deaths from AIDS-related
More informationEnding AIDS in Gabon: How long will it take? How much will it cost?
Ending AIDS in Gabon: How long will it take? How much will it cost? Brian G. Williams, Eleanor Gouws* and David Ginsburg South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch,
More informationSubmitted electronically to:
Submitted electronically to: ODOARRFI19@nih.gov Maureen Goodenow, PhD Associate Director of AIDS Research, NIH Director, Office of AIDS Research (OAR) National Institutes of Health 5601 Fishers Lane. Room
More informationState of Alabama HIV Surveillance 2012 Annual Report Finalized
State of Alabama HIV Surveillance 2012 Annual Report Finalized Prepared by: Division of HIV/AIDS Prevention and Control HIV Surveillance Branch Contact Person: Allison R. Smith, MPH Allison.Smith@adph.state.al.us
More informationHIV Viral Load Testing Market Analysis. September 2012 Laboratory Services Team Clinton Health Access Initiative
HIV Viral Load Testing Market Analysis September 2012 Laboratory Services Team Clinton Health Access Initiative Agenda Background on Viral Load Testing Growth of Global Viral Load Market Factors Impacting
More information2018 INFUSE CALL FOR INNOVATION
2018 INFUSE CALL FOR INNOVATION Leveraging digital technologies for registration, identification, digital record-keeping and follow-up to ensure healthier futures Imagine a future in which all children
More informationRoche to provide HIV diagnostic solutions to Global Fund. Framework agreement with Global Fund strengthens access to HIV diagnostics
Media Release June 18, 2015 Roche to provide HIV diagnostic solutions to Global Fund Framework agreement with Global Fund strengthens access to HIV diagnostics Roche (SIX: RO, ROG; OTCQX: RHHBY) announced
More informationThe economic impact of quarantine: SARS in Toronto as a case study Gupta A G, Moyer C A, Stern D T
The economic impact of quarantine: SARS in Toronto as a case study Gupta A G, Moyer C A, Stern D T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationMichigan s Diabetes Crisis: Today and Future Trends. Dr. William Rowley Institute for Alternative Futures
Michigan s Diabetes Crisis: Today and Future Trends Dr. William Rowley Institute for Alternative Futures 1 What s Happening to Our Children? During their lifetimes: 1/2 will become obese 1 in 3 males &
More informationMultisectoral action for a life course approach to healthy ageing
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY Provisional agenda item 14.4 21 March 2014 Multisectoral action for a life course approach to healthy ageing 1. The attached document EB134/19 was considered and noted
More informationModule 6: Substance Use
Module 6: Substance Use Part 1: Overview of Substance Abuse I am Martha Romney and I am presenting on substance abuse. This module focuses on the healthy people 2020 objective to reduce substance abuse
More informationTHE PERRYMAN GROUP. 510 N. Valley Mills Dr., Suite 300. Waco, TX ph , fax
November 2014 An Economic Assessment of the Cost of Cancer in Texas and the Benefits of the Cancer Prevention and Research Institute of Texas (CPRIT) and its Programs: 2014 Update THE PERRYMAN GROUP 510
More informationMinneapolis Department of Health and Family Support HIV Surveillance
Rate per 1, persons 2 21 22 23 24 25 26 27 28 29 21 Rate per 1, persons Minneapolis Department of Health and Family Support HIV Surveillance Research Brief, September 212 Human immunodeficiency virus (HIV)
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationCaribbean Actuarial Association
Caribbean Actuarial Association Pandemic Coverage Presented by Annemarie Brownmiller Consulting Services of Princeton, LLC atbrownmiller@comcast.net D. Grenville MacDonald Park Re Canada gmacdonald@parkrecanada.com
More informationCost-effectiveness of cesarean section delivery to prevent mother-to-child transmission of HIV-1 Halpern M T, Read J S, Ganoczy D A, Harris D R
Cost-effectiveness of cesarean section delivery to prevent mother-to-child transmission of HIV-1 Halpern M T, Read J S, Ganoczy D A, Harris D R Record Status This is a critical abstract of an economic
More information1.2 Building on the global momentum
1.1 Context HIV/AIDS is an unprecedented global development challenge, and one that has already caused too much hardship, illness and death. To date, the epidemic has claimed the lives of 20 million people,
More informationAcyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: a cost-effectiveness analysis Little S E, Caughey A B
Acyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: a cost-effectiveness analysis Little S E, Caughey A B Record Status This is a critical abstract of an economic evaluation
More informationSource of effectiveness data The effectiveness data were derived from a review of completed studies and authors' assumptions.
Cost-effectiveness of hepatitis A-B vaccine versus hepatitis B vaccine for healthcare and public safety workers in the western United States Jacobs R J, Gibson G A, Meyerhoff A S Record Status This is
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationThe Economic Cost of Non-adherence to TB Medicines Resulting from Stock-outs and Loss to Follow-up in Kenya
The Economic Cost of Non-adherence to TB Medicines Resulting from Stock-outs and Loss to Follow-up in Kenya March 2017 Photo Credit: Francis Nsanga UHMG, Photoshare, Kenya RESEARCH SUMMARY A key element
More informationTHE VALUE OF JOINT REPLACEMENT IN TREATING PATIENTS WITH OSTEOARTHRITIS
THE VALUE OF JOINT REPLACEMENT IN TREATING PATIENTS WITH OSTEOARTHRITIS Total Joint Replacement is a valuable treatment option for many of the 27 million Americans who suffer from Osteoarthritis, a disease
More informationHana Ross, PhD American Cancer Society and the International Tobacco Evidence Network (ITEN)
The Costs of Smoking Hana Ross, PhD American Cancer Society and the International Tobacco Evidence Network (ITEN) Why Do We Study the Cost of Smoking? To assess the economic impact of smoking behavior
More informationReturn on Public Health Investment: CDC s Expanded HIV Testing Initiative ACCEPTED
JAIDS Journal of Acquired Immune Deficiency Syndromes Publish Ahead of Print DOI: 10.1097/QAI.0b013e31823e5bee 10.7.11 Return on Public Health Investment: CDC s Expanded HIV Testing Initiative Angela B
More informationMMWR Analysis Provides New Details on HIV Incidence in U.S. Populations
MMWR Analysis Provides New Details on HIV Incidence in U.S. Populations CDC HIV/AIDS Fa c t s S e p t e m b e r 2008 On August 6, 2008, the Centers for Disease Control and Prevention (CDC) released a new
More informationSTOP HIV/AIDS Pilot Project
STOP HIV/AIDS Pilot Project QUARTERLY INDICATORS REPORT: 1 April through 30 June 2011 () SUBMITTED TO: The BC Ministry of Health Services SUBMITTED BY: Dr. Rolando Barrios, Dr. Mark Gilbert, Dr. Kate Health,
More informationProposed Strategy for Epilepsy Care in Ontario
803 3100 Steeles Avenue East, Markham, ON L3R 8T3 T:905 474 9696 TF: 800 463 1119 Proposed Strategy for Epilepsy Care in Ontario Epilepsy agencies in Ontario applaud Health Quality Ontario, the Ontario
More informationChampioning patients every step of the way
Championing patients every step of the way The majority of people living with a rare disease have no treatment for their condition. At Shire, we have long believed we have a unique opportunity to champion
More informationHIV Housing Care Continuum Webinar 1 August 3, 2016
Page 1 HIV Housing Care Continuum August 3, 2016 Rita Flegel: Hello and welcome. I'm Rita Flegel, the Director of HUD's Office of HIV/AIDS Housing. And presenting with me today is Amy Palilonis also from
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide
Transmitted by Jonathan Nurse, Director of Government Relations, IDSA The Infectious Diseases Society of America s (IDSA) Fiscal Year 2015 Funding Statement Submitted to the House Appropriations Subcommittee
More informationASSESSING THE VALUE OF BIOPHARMACEUTICAL INNOVATION IN KEY THERAPY AREAS IN MIDDLE-INCOME COUNTRIES
ASSESSING THE VALUE OF BIOPHARMACEUTICAL INNOVATION IN KEY THERAPY AREAS IN MIDDLE-INCOME COUNTRIES TIM WILSDON JIM ATTRIDGE EVA FIZ SATOMI GINOZA ADAM MITCHELL-HEGGS KEY FINDINGS THE INTERNATIONAL FEDERATION
More informationSetting The setting was community. The economic study was carried out in the USA.
Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children Lieu T A, Ray G T, Black S R, Butler J C, Klein J O, Breiman R F, Miller M A, Shinefield H R Record
More informationDemocratic Republic of Congo Country Report FY14
USAID ASSIST Project Democratic Republic of Congo Country Report FY14 Cooperative Agreement Number: AID-OAA-A-12-00101 Performance Period: October 1, 2013 September 30, 2014 DECEMBER 2014 This annual country
More informationNorthern Alberta preventing HIV transmission to babies
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Northern Alberta preventing HIV transmission to babies 25 June 2009 Since 1996 the widespread availability of combination therapy for HIV
More informationPatients with persistently low CD4 counts on antiretroviral
Predicting HIV Care Costs Using CD4 Counts From Clinical Trials Andrew Hill, PhD; and Kelly Gebo, MD, MPH Objective: To predict the effects of a new antiretroviral agent on the costs of care in a US HIV
More informationThe Journey towards Total Wellbeing A Health System s Innovative Approach
The Journey towards Total Wellbeing A Health System s Innovative Approach Company Profile Wellness A state of complete physical, mental and social wellbeing and not merely the absence of disease or infirmity
More informationCost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers Scheid D C, Hamm R M, Stevens K W
Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers Scheid D C, Hamm R M, Stevens K W Record Status This is a critical abstract of an economic evaluation
More informationAn Online Cost Calculator for Estimating the Economic Cost of Illness Due to Shiga Toxin- Producing E. coli (STEC) O157 Infections
United States Department of Agriculture Economic Research Service Economic Information Bulletin Number 28 An Online Cost Calculator for Estimating the Economic Cost of Illness Due to Shiga Toxin- Producing
More informationFULTON COUNTY GOVERNMENT RYAN WHITE PART A PROGRAM. Atlanta Eligible Metropolitan Area HIV/AIDS Unmet Need Estimate
FULTON COUNTY GOVERNMENT RYAN WHITE PART A PROGRAM Atlanta Eligible Metropolitan Area HIV/AIDS Unmet Need Estimate Southeast AIDS Training and Education Center Department of Family and Preventative Medicine
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Enfuvirtide (Fuzeon) Reference Number: CP.PHAR.41 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationNew Jersey s Comprehensive Tobacco Control Program: Importance of Sustained Funding
New Jersey s Comprehensive Tobacco Control Program: Importance of Sustained Funding History of Tobacco Control Funding Tobacco use is the leading preventable cause of death in the U.S., killing more than
More informationThe impact of pharmaceutical innovation on New Zealand cancer patients
The impact of pharmaceutical innovation on New Zealand cancer patients Frank R. Lichtenberg, Ph.D Columbia University and National Bureau of Economic Research New medicines have helped people with cancer
More informationCost-effectiveness of HIV post-exposure prophylaxis in France Herida M, Larsen C, Lot F, Laporte A, Desenclos J C, Hamers F F
Cost-effectiveness of HIV post-exposure prophylaxis in France Herida M, Larsen C, Lot F, Laporte A, Desenclos J C, Hamers F F Record Status This is a critical abstract of an economic evaluation that meets
More informationStatement Of. The National Association of Chain Drug Stores. For. U.S. Senate Finance Committee. Hearing on:
Statement Of The National Association of Chain Drug Stores For U.S. Senate Finance Committee Hearing on: 10:30 a.m. 215 Dirksen Senate Office Building National Association of Chain Drug Stores (NACDS)
More informationCost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation Nielsen K, Fiore M C
Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation Nielsen K, Fiore M C Record Status This is a critical abstract of an economic evaluation that meets the
More informationProtecting the gains: what changes are needed to prevent a reversal of the downward CVD mortality trend?
Protecting the gains: what changes are needed to prevent a reversal of the downward CVD mortality trend? Abstract 117 Jesse D Ortendahl 1, Allison L Diamant 2, Peter P Toth 3, Dasha Cherepanov 1, Amanda
More informationCenters for Disease Control and Prevention s Office on Smoking and Health
Centers for Disease Control and Prevention s Office on Smoking and Health Tobacco use remains the leading cause of preventable death in the United States, killing more than 480,000 Americans every year,
More informationThe Heterosexual HIV Epidemic in Chicago: Insights into the Social Determinants of HIV
The Heterosexual HIV Epidemic in Chicago: Insights into the Social Determinants of HIV Nikhil Prachand, MPH Board of Health Meeting January 19, 2011 STI/HIV/AIDS Division Today s Presentation Epidemiology
More informationA conservative estimate of annual costs for lead poisoning, asthma, cancer and selected neurodevelopmental disabilities A report prepared by
The Price of Pollution: Cost Estimates of Environment-Related Childhood Disease in Michigan A conservative estimate of annual costs for lead poisoning, asthma, cancer and selected neurodevelopmental disabilities
More informationSTATE STRATEGY to Combat the Spread of HIV in Russia through 2020 and beyond
UNOFFICIAL TRANSLATION APPROVED by the Federal Government on October 20, 2016 STATE STRATEGY to Combat the Spread of HIV in Russia through 2020 and beyond I. General provisions State Strategy to Combat
More informationThe Value of Providing Collaborative Care Models For Treating Employees with Depression
The Value of Providing Collaborative Care Models For Treating Employees with Depression Summary Depression is one of the costliest health issues for employers because of its high prevalence and co-morbidity
More informationEconomic Evaluation. Introduction to Economic Evaluation
Economic Evaluation Introduction to Economic Evaluation This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More information1201 Maryland Avenue SW Suite 900 Washington, DC
June 14, 2012 Lonnie King, D.V.M. Chair Committee on Identifying and Prioritizing New Preventive Vaccines for Development Institute of Medicine 500 Fifth Street, NW Washington, DC 20001 Re: Ranking Vaccines:
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More information